Source:http://linkedlifedata.com/resource/pubmed/id/15388253
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-9-24
|
pubmed:abstractText |
Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Immune Sera,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Inactivated,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0165-2478
|
pubmed:author |
pubmed-author:FanJiang-linJL,
pubmed-author:LiJiu-XiangJX,
pubmed-author:LiuShi-ShengSS,
pubmed-author:LiuXin-JianXJ,
pubmed-author:LuJia-HaiJH,
pubmed-author:MengMin-JieMJ,
pubmed-author:QianChui-WenCW,
pubmed-author:WanZhuo-YueZY,
pubmed-author:WangYi-FeiYF,
pubmed-author:XiongShengS,
pubmed-author:YanXin-GeXG,
pubmed-author:ZhangChuan-HaiCH,
pubmed-author:ZhangMei-YingMY,
pubmed-author:ZhengHuan-YinHY
|
pubmed:issnType |
Print
|
pubmed:volume |
95
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
139-43
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15388253-Animals,
pubmed-meshheading:15388253-Antibodies, Viral,
pubmed-meshheading:15388253-Antibody Specificity,
pubmed-meshheading:15388253-Antigens, Viral,
pubmed-meshheading:15388253-Immune Sera,
pubmed-meshheading:15388253-Immunoglobulin G,
pubmed-meshheading:15388253-Kinetics,
pubmed-meshheading:15388253-Mice,
pubmed-meshheading:15388253-Mice, Inbred BALB C,
pubmed-meshheading:15388253-Neutralization Tests,
pubmed-meshheading:15388253-SARS Virus,
pubmed-meshheading:15388253-Severe Acute Respiratory Syndrome,
pubmed-meshheading:15388253-Vaccines, Inactivated,
pubmed-meshheading:15388253-Viral Vaccines
|
pubmed:year |
2004
|
pubmed:articleTitle |
Immunogenicity of SARS inactivated vaccine in BALB/c mice.
|
pubmed:affiliation |
Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|